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Abstract
Germline mutations in the cyclin-dependent kinase inhibitor 2A gene (CDKN2A) are frequently 
identified among melanoma kindreds, and are associated with increased atypical nevus counts. 
However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus 
phenotypes including counts of common acquired nevi has not yet been established. Using data 
from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2 
mm, 5 mm, and atypical nevus counts among blood-related members of melanoma families. 
Compared to individuals without a pathogenic mutation, those who carried one had an overall 
higher prevalence of atypical (OR=1.64; 95% CI: 1.18, 2.28) nevi, but not 2 mm nevi (OR=1.06; 
95% CI: 0.92, 1.21) or 5 mm nevi (OR=1.26; 95% CI: 0.94, 1.70). Stratification by case status 
revealed more pronounced positive associations among non-case family members, who were 
nearly three times (OR=2.91; 95% CI: 1.75, 4.82) as likely to exhibit nevus counts at or above the 
median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not 
harboring one). Our results are supportive of the hypothesis that unidentified nevogenic genes are 
co-inherited with CDKN2A and may influence carcinogenesis.
Introduction
Germline mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene are 
frequently identified in familial melanoma (Goldstein et al., 2006; Goldstein et al., 2007), 
with prevalence in families with three or more members diagnosed with melanoma ranging 
between 20 and 50% (Goldstein and Tucker, 2001; Harland et al., 2014; Kefford et al., 
1999). In contrast, these mutations account for only 1–2% of population-based melanoma 
cases (Harland et al., 2014). Germline mutations in CDKN2A have also been associated 
with familial atypical multiple mole melanoma (FAMMM) syndrome, an autosomally 
dominant condition exemplified by a family history of melanoma and high numbers of 
atypical nevi (Eckerle Mize et al., 2009; Goldstein et al., 2007). However, estimating the 
prevalence of FAMMM has been difficult due to intra- and inter-family variability in the 
FAMMM phenotype (Goldstein et al., 2000; Lynch et al., 2002; Rulyak et al., 2003), and a 
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clear relationship between CDKN2A mutation classification and number of atypical nevi has 
not yet been established (Bishop et al., 2000; de Snoo et al., 2008; Nielsen et al., 2010).
Few studies have examined the relationship between germline CDKN2A mutational status 
and number of common melanocytic nevi among melanoma families, even though evidence 
from previous genome-wide association studies (GWAS) suggests that variation near the 
CDKN2A locus is associated with nevus count (Barrett et al., 2011; Falchi et al., 2009). 
Here, we evaluate associations between germline CDKN2A pathogenic mutation 
classification and nevus phenotype among participants in research performed by the 
GenoMEL consortium (www.genomel.org). A better understanding of CDKN2A’s influence 
on nevogenesis among blood-related cases and non-cases of melanoma may aid in the search 
of other risk modifying nevogenic genes. In addition, robust phenotypic indicators of 
CDKN2A pathogenic mutation carriers, especially among non-case members (i.e. 
individuals who have not been diagnosed with melanoma) of melanoma families, could 
influence clinicians’ surveillance and prevention strategies in this high-risk population.
Results
CDKN2A genotype was available for at least one member of 896 (78%) families comprising 
3,990 individuals, of whom 1,651 (41%) also submitted to nevus phenotyping (Table 1). All 
analyses were confined to this final analytic cohort of 1,651 participants. The median values 
of 2 mm, 5 mm, and atypical nevus counts were similar among those with and without a 
pathogenic CDKN2A mutation, although we observed a higher degree of variation among 
pathogenic mutation carriers compared to those without a pathogenic mutation (Figure 1). 
Total nevus count (i.e. the sum of 2 mm, 5 mm, and atypical nevus counts) was highly 
correlated (r=0.99) with number of 2 mm nevi. Median 2 mm nevus counts for those with 
and without a pathogenic mutation were 54 (interquartile range (IQR)=102) and 47 
(IQR=87) respectively. For 5 mm nevus counts, those with a pathogenic mutation had a 
median value of 2 (IQR=5) whereas a median value of 1 (IQR=5) was observed among 
individuals without a pathogenic mutation. Those with and without a pathogenic mutation 
had a median value of 0 for atypical nevus counts with an IQR of 2 for pathogenic mutation 
carriers and 1 for those without a pathogenic mutation.
Compared to individuals without a pathogenic CDKN2A mutation, pathogenic mutation 
carriers had an overall higher prevalence of atypical nevi (OR=1.64; 95% CI: 1.18, 2.28). 
Moreover, pathogenic mutation carriers were almost twice as likely as those without a 
pathogenic mutation (OR=1.83; 95% CI: 1.25, 2.67) to exhibit nevus counts at or above the 
center-specific medians in all three categories of nevi (mole gestalt scores of 3 vs. 0). 
Pathogenic CDKN2A mutation carriage was not associated with common acquired (2 mm, 5 
mm) nevus counts (Table 2). Total nevus count was not associated with carriage of 
CDKN2A mutations and, as expected, point estimates were nearly identical to those 
observed for 2 mm nevus counts (data not tabulated).
Upon stratification by melanoma case status, we observed more pronounced positive 
associations between CDKN2A pathogenic mutation carriage and nevus counts among the 
non-case family members. Among non-case participants, those harboring a pathogenic 
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mutation were nearly three times as likely to demonstrate the highest mole gestalt score (3 
vs. 0) compared to those without a pathogenic mutation (OR=2.91; 95% CI: 1.75, 4.82) and 
exhibited approximately twice as many atypical nevi compared to non-cases without a 
pathogenic mutation (OR=1.98; 95% CI: 1.34, 2.90). In contrast, carriage of a pathogenic 
mutation among melanoma cases was inversely associated with mole gestalt score (3 vs. 0) 
compared to those without a pathogenic mutation (OR=0.90; 95% CI: 0.53, 1.53) and 
showed a modest, but statistically nonsignificant, positive association with number of 
atypical nevi compared to wildtype carriage (OR=1.47; 95% CI: 0.92, 2.33) (Table 2).
We further explored associations stratified by GenoMEL study centers grouped according to 
proximity to the equator to assess the relative influence of increasing daylight hours; and one 
stratified by anatomic site of first melanoma classified by relative duration of UV exposure. 
Latitude did not demonstrate a statistically significant influence on the association between 
any CDKN2A mutation carriage and nevus phenotype (p-interaction >0.05 for all nevus 
phenotype categories), nor could we discern any clear patterns of association according to 
relative UV exposure of anatomic site of first verified melanoma (Supplemental Tables 2 and 
3).
Discussion
Within melanoma families, we observed higher mole gestalt scores among pathogenic 
CDKN2A mutation carriers compared to those without a pathogenic mutation, indicating 
that carriers tended to have more nevus laden phenotypes. Estimates within individual nevus 
phenotype categories (i.e. 2 mm, 5 mm, and atypical nevus counts) indicate pathogenic 
mutation carriers exhibit greater numbers of atypical nevi compared to non-carriers.
To date, few studies have examined the influence of germline CDKN2A mutation carriage 
on common acquired nevus counts among melanoma-prone families. A longitudinal study of 
a large melanoma family from Utah reported increasing nevus counts among carriers of the 
specific V126D mutation compared to wildtype over a 15 year interval (Florell et al., 2004). 
However, the impact of the mutation on atypical nevi is unclear as total nevus count was 
reported. Twin studies identified a quantitative-trait locus (microsatellite marker D9S942) 
for nevus density in a noncoding region of CDKN2A (Falchi et al., 2006; Zhu et al., 1999; 
Zhu et al., 2007), which may suggest a broader role of CDKN2A in nevogenesis among the 
majority of individuals who do not harbor a rare germline mutation. However, an adolescent 
twin study from the UK found no evidence for D9S942 as a quantitative-trait locus 
influencing nevus density (Barrett et al., 2003) and a familial-based investigation of a 
potentially nevogenic variant (A148T) near D9S942 also found no association with common 
acquired nevus counts (Bertram et al., 2002). Germline mutations in CDKN2A are strongly 
associated with FAMMM syndrome, and individual members of these families often have 
abundant numbers of atypical and common nevi (Gruis et al., 1995; Hussussian et al., 1994; 
Soura et al., 2016). However, not all individuals with CDKN2A mutations present with 
excessive or even higher nevus counts. Studies of Dutch and Swedish melanoma kindreds 
have reported low atypical and common nevus counts among CDKN2A mutation carriers 
(Ipenburg et al., 2016; Nielsen et al., 2010). Similar findings were reported among 
melanoma families from the UK (Newton Bishop et al., 1994). The range of atypical nevi 
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(0–94) observed in GenoMEL family members with pathogenic CDKN2A mutations further 
highlights the influence of CDKN2A on phenotypic heterogeneity.
Evaluating individual nevus types among GenoMEL participants suggests that germline 
pathogenic mutations at CDKN2A are more predictive of number of atypical nevi compared 
to common acquired nevi (2 mm and 5 mm nevi), a result which is consistent with previous 
findings (Bishop et al., 2000). These results are also interesting in light of recent research 
that suggests intermediate lesions, a classification that includes atypical/dysplastic nevi, are 
likely to exhibit hemizygous loss of CDKN2A, supporting a role for this locus in the 
development of histological atypia in nevi (Shain et al., 2015). It is important to note that the 
defining criteria of atypical nevi in the present study were clinical and not pathologically-
based; it is possible that very subtle atypical nevi could have been misclassified as 5 mm 
nevi. Furthermore, although we took a conservative approach when assigning pathogenicity 
to CDKN2A variants/mutations, it is possible that our designation of some common variants 
as not pathogenic is not accurate. We based our assessment on evidence of a deleterious 
effect, and for some of the common variants there is no such evidence to date.
Our observation of distinct differences in associations according to case status is interesting. 
Non-case members of melanoma-prone families demonstrated relatively strong associations 
of CDKN2A pathogenic mutation carriage with mole gestalt score and number of atypical 
nevi, while corresponding associations among case family members tended to be attenuated. 
Pathogenic germline mutations in CDKN2A and number of nevi are both important risk 
factors for melanoma. The observed pronounced difference in the relationship between 
CDKN2A mutational status and nevus phenotype according to case status may be due, in 
part, to the higher proportion of pathogenic CDKN2A mutations among cases (42%) 
compared to non-cases (25%). If CDKN2A influences nevogenesis, we might expect to see 
diminished associations between pathogenic CDKN2A mutation carriage and nevus 
phenotype among cases compared to non-cases. The higher nevus count distributions we 
observed among cases compared to non-cases tends to support this hypothesis 
(Supplemental Figure 1). It is also possible that case members are affected by yet-to-be-
discovered nevogenic genes that cosegregate with CDKN2A and either modify CDKN2A’s 
nevogenic function or influence nevogenesis independently. Another possible explanation is 
that non-case family members may be more likely to inherit unidentified lower penetrance 
genes that are important risk modifiers of nevus formation, potentially hinder melanoma 
initiation, and cosegregate with CDKN2A.
Zhu et al. have speculated that environmental factors affecting spontaneous somatic 
mutation rates (e.g. UV exposure) in tumor suppressor genes may help to explain nevus 
count variation between individuals as well as familial correlations in nevus counts (Zhu et 
al., 2007). However, our analyses by latitude of ascertainment center and anatomic site of 
melanoma—arguably two proxy measures of UV exposure—did not reveal meaningful 
nevus phenotype differences across strata. This exploratory analysis did not take into 
consideration behaviors that influence UV exposure (e.g. sunbathing/tanning, sunscreen 
usage, apparel).
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In summary, our results are consistent with previous studies reporting that CDKN2A plays a 
role in nevogenesis (Bishop et al., 2000; Cannon-Albright et al., 1994; Florell et al., 2004; 
Shain et al., 2015; Zhu et al., 1999). In general, pathogenic mutation carriers are 
significantly more likely to exhibit higher than median nevus counts in all three categories of 
nevus phenotype simultaneously compared to those without a pathogenic CDKN2A 
mutations, as evidenced by our mole gestalt score results. Acknowledging the potential 
nevus phenotype overlap between those with and without a pathogenic CDKN2A mutation 
(Bishop et al., 2000), we examined associations based on case status among melanoma 
family members. Associations between CDKN2A pathogenic mutational status and nevus 
phenotype according to case status contrasted sharply. These differences may be explained if 
CDKN2A possesses a degree of nevogenic function since case family members exhibited 
higher nevus counts and were more likely to harbor a pathogenic CDKN2A mutation 
compared to non-case members, which could result in diminished associations among case 
members. Our findings are generally supportive of the hypothesis that unidentified 
nevogenic genes are co-inherited with CDKN2A (Florell et al., 2004).
Materials & Methods
Over the past two decades, GenoMEL has aggregated data from individuals belonging to 
melanoma families from around the globe. We refer to participants with a melanoma 
diagnosis at the time of recruitment as cases, whereas family members who had not been 
diagnosed with melanoma at the time of recruitment are referred to as non-cases. Currently, 
GenoMEL consists of 29 centers from Australia, Europe, the Middle East, and North and 
South America.
GenoMEL employed a common protocol for data collection from prospectively enrolled 
participants, although family identification and recruitment procedures were allowed to 
differ among study centers. Additionally, centers had a degree of autonomy over the data 
collection process, which resulted in different contributions across various protocol 
components. Thus, not all centers completed all portions of the research protocol for each 
enrolled participant. Regulatory approval was obtained by the institutional review boards of 
each GenoMEL study center, and written informed consent was obtained for each 
participant. Individuals who signed informed consent were asked about their personal and 
familial melanoma history and to submit to a full phenotypic examination by research staff, 
which included an evaluation of nevus counts by anatomic site. Training was carried out for 
all staff performing phenotyping on participants in the prospective study in the UK. 
Consolidation of that training was subsequently carried out in Italy. Several GenoMEL study 
centers had extant data previously collected from members of melanoma families under 
local regulatory approval, and where possible this information was harmonized with data 
arising from participants enrolled in the prospective GenoMEL study.
A melanoma family was defined by the presence of three or more cases of confirmed 
cutaneous melanoma in the same lineage, or two cases of confirmed cutaneous melanoma in 
first-degree relatives. Melanoma case family members with a diagnosis of mucosal or ocular 
melanoma did not contribute to defining a melanoma family and were excluded from 
analysis. Confirmation of diagnosis was made by: pathology report (75%), physician letter 
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or clinical document verifying melanoma diagnosis (19%), death certificate (2%), or cancer 
registry data (4%). Individuals who are members of melanoma families by virtue of 
marriage and not ancestry, or for whom family relationship information was ambiguous or 
missing, were excluded from this study. Family members who reported a melanoma, but for 
whom verification of diagnosis was not available, were also excluded from analyses.
Nevi ≥ 2 mm but <5 mm in diameter (hereinafter referred to as 2 mm nevi) were counted on 
exposed skin, in addition to nevi ≥ 5 mm in diameter (hereinafter referred to as 5 mm nevi) 
and clinically atypical nevi; sites not examined were the genitalia and female breasts. An 
atypical nevus was defined as a nevus ≥ 5 mm in diameter and containing a flat component, 
with at least two of the following characteristics: variable pigmentation, asymmetrical shape 
or diffuse border. We also derived a summary variable from 2 mm, 5 mm, and atypical nevus 
counts to describe an individual’s overall nevus phenotypic landscape. Specifically, 
individuals were assigned a dichotomous score within each category of 2 mm, 5 mm, and 
atypical nevus count according to the study center-specific median. Individuals with at least 
the median nevus count were scored as 1, with those exhibiting fewer than the median nevus 
count scored as 0; each individual then received an aggregate “mole gestalt” summary score 
between 0 and 3 based on the sum of these three dichotomous scores.
Germline DNA of consenting participants was screened for mutations in CDKN2A (exons 
1α, 1β, 2 and 3) as previously described (Harland et al., 2008). Mutation evaluation, 
predominantly by sequencing or denaturing high performance liquid chromatography 
followed by sequencing, was conducted at each study center. Previous evaluation has 
confirmed consistent mutation detection across the consortium (Harland et al., 2008). 
Sequencing results were collated and mutational status was assigned according to 
pathogenicity as outlined in Supplemental Table 1. Briefly, pathogenic variants were 
adjudicated based on demonstrated (i.e. published) impact on the biological function of 
CDKN2A or bioinformatically inferred deleterious impact on CDKN2A function, and 
evidence of cosegregation within melanoma families. Variants not meeting any of these 
criteria were classified as benign (Taylor et al., 2016). Individual participants were classified 
based on presence of a pathogenic mutation; benign variant carriers and wildtype individuals 
were combined for analyses and classified as having “no known pathogenic” mutations at 
CDKN2A. Individuals who carried both a pathogenic mutation and a benign mutation were 
classified as pathogenic.
We used the generalized estimating equation (GEE) method implemented in SAS v.9.4 (SAS 
Institute, Cary, NC) to calculate odds ratios and 95% confidence intervals for associations 
between nevus phenotypes and CDKN2A mutational status. For our nevus count outcomes 
we used Poisson regression (2 mm nevi) or negative binomial regression when nevus counts 
were right skewed (5 mm and atypical nevi), whereas a multinomial model was used to 
evaluate the “mole gestalt” variable. Designating a Type I. error rate of α=0.05, we 
performed score tests of the null hypothesis that no differences exist between nevus counts 
within strata of mutational status. Analyses were adjusted for age at phenotyping, sex, the 
interaction between age and sex, melanoma status and, study center, and we accounted for 
the non-independence of observations arising from familial clustering within study center 
using the repeated subject statement of the GENMOD SAS procedure.
Taylor et al. Page 7













We examined associations by latitude by grouping GenoMEL ascertainment centers 
according to equatorial proximity. Among family members with a diagnosis of melanoma, 
we also examined associations between CDKN2A mutational status and nevus phenotype by 
anatomic location of an individual’s first verified melanoma. Anatomic sites were classified 
as those usually exposed (head, neck, lower arms and scalp-male), intermittently exposed 
(trunk, back, upper arms, lower legs, and scalp-female), and usually unexposed (buttock, 
upper legs) to UV radiation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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2 mm, 5 mm, and atypical nevus count distributions among GenoMEL melanoma family 
members across all ascertainment centers according to CDKN2A mutational status. Crude 
nevus counts are plotted and are not representative of center-specific measures adopted for 
statistical modeling. Heavy horizonal lines indicate 50th percentile counts, boxes indicate 
25th and 75th percentile counts, whiskers indicate 5th and 95th percentile counts, and circles 
represent values in the top or bottom 5% of counts.
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Table 1
CDKN2A status in melanoma families and family members participating in the GenoMEL Study by 
ascertainment center*
Center Total # of families Number of families with ≥1 
member who is CDKN2A 
genotyped
Number of family 
members with known 
CDKN2A genotype
Number of family members 
phenotyped with known 
CDKN2A genotype
Barcelona, ES 25 25 116 83
Bethesda, US 49 48 782 468
Cesena, IT 24 24 116 17
Copenhagen, DK 18 15 18 0
Genoa, IT 14 14 45 31
Leeds, GB 76 74 282 216
Leiden, NL 61 59 600 240
Ljubljana, SI 4 4 11 10
Lund, SE 8 8 97 74
Montevideo, UY 4 4 23 23
Paris, FR 181 181 588 161
Philadelphia, US 36 36 104 47
Porto Alegre, BR 10 5 12 4
Queensland, AU 230 22 172 11
Riga, LV 5 5 8 5
Salt Lake City, US 1 1 3 3
Santiago, CL 2 2 6 6
São Paulo, BR 12 7 28 25
Stockholm, SE 27 25 118 113
Sydney, AU 319 311 820 85
Tel Aviv, IL 28 21 25 25
Valencia, ES 15 5 16 4
Total 1,149 896 3,990 1,651
*
Melanoma families are defined by 3 or more members with a verified melanoma or 2 first degree relatives with verified melanomas. Married-in 
relatives not belonging to a melanoma family lineage are excluded.
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